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Background: Fabrication of a smart drug delivery system that could dramatically increase the
efficiency of chemotherapeutic drugs and reduce the side effects is still a challenge for
pharmaceutical researchers. By the emergence of nanotechnology, a huge window was opened
towards this goal, and a wide type of nanocarriers were introduced for delivering the che-
motherapeutic to the cancer cells, among them are cyclodextrins with the ability to host
different types of hydrophobic bioactive molecules through inclusion complexation process.
Aim: The aim of this study is to design and fabricate a pH-responsive theranostic nanocap-
sule based on cyclodextrin supramolecular nano-structure.
Materials and methods: This nanostructure contains iron oxide nanoparticles in the core
surrounded with three polymeric layers including polymeric β-cyclodextrin, polyacrylic
acid conjugated to sulfadiazine, and polyethylenimine functionalized with β-cyclodextrin.
Sulfadiazine is a pH-responsive hydrophobic component capable of making inclusion
complex with β-cyclodextrin available in the first and third layers. Doxorubicin, as an
anti-cancer drug model, was chosen and the drug loading and release pattern were
determined at normal and acidic pH. Moreover, the biocompatibility of the nanocapsule
(with/without drug component) was examined using different techniques such as MTT
assay, complement activation, coagulation assay, and hemolysis.
Results: The results revealed the successful preparation of a spherical nanocapsule with
mean size 43±1.5 nm and negatively charge of −43 mV that show 160% loading efficacy.
Moreover, the nanocapsule has an on/off switching release pattern in response to pH that
leads to drug released in low acidic pH. The results of the biocompatibility tests indicated
that this nano drug delivery system had no effect on blood and immune components while
it could affect cancer cells even at very low concentrations (0.3 μg mL−1).
Conclusion: The obtained results suggest that this is a “switchable” theranostic nanocapsule
with potential application as an ideal delivery system for simultaneous cancer diagnosis and
therapy.
Keywords: nanocapsule, host-guest interaction, on/off switching, pH-responsive, smart
nanocarrier
Introduction
Finding an effective method for the treatment of cancer, as an incurable, progres-
sive illness, has attracted lots of attention. Conventional chemotherapy, as one of
the most frequently used methods for cancer treatment, is carried out based on non-
targeted drug delivery to cancer cells that in turn, is associated with undesirable
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side-effects on normal cells. In fact, the common anti-
cancer drugs have several drawbacks, including poor
water solubility, immune system activation, and fast elim-
ination from the body, leading to insufficient delivery to
the tumors and suboptimal therapeutic activity. Therefore,
design and fabrication of a drug delivery system with
prominent properties for cancer therapy is the aim of
variety of researches.1–5
The emergence of nanoscience and nanotechnology
created many hopes for the treatment of various diseases
through the introduction of novel strategies. One of the
most interesting fields of nanotechnology in medicine and
pharmacology is the fabrication of nanocarriers for speci-
fic delivery of drugs to the target site. These nanocarriers
are classified in certain categories and can act as a mask
for the drugs leading to an increase in the bioavailability of
the drugs by protecting them from blood clearance through
immune system factors.6–9
Using stimuli triggers introduce a new class of carriers
entitled smart nano-systems, which could release their
cargo in response to a specific physiological feature, at
the appropriate time, right site and suitable dose. These
stimuli trigger are categorized into three main classes:
chemical (pH, ionic strength), physical (light, magnetic,
and temperature) and biological (enzymes, and receptor)
stimulation. The unique property of smart delivery systems
in releasing their drug cargo in the presence of a specific
condition could increase the therapeutic efficiency along
with decrease in the side effects of the drugs.10–13
Integrating therapeutic properties of these types of
nano-systems with diagnosis features could lead to pro-
duce multifunctional nanocarriers recognized as smart
nano-theranostics. Nano-theranostics are a class of nano-
systems with the ability of simultaneous diagnosis and
therapy, in which the diagnostic material emerges as the
therapeutic agent itself or in combination with a therapeu-
tic species. So far, several types of nanomaterials have
been introduced with the ability to enhance the quality of
imaging techniques like magnetic nanoparticles in mag-
netic resonance imaging (MRI), gold nanoparticles in
computed tomography (CT), and graphene oxide nano-
sheets and quantum dots in fluorescence diagnosis.14–17
Among different types of nanocarriers, hollow nano-
capsules are one of the most important classes, which
consist of a hole surrounded by one or more polymeric
shells in the size of nanometers (10–1000 nm), that have
the ability of drug entrapment in their internal space. There
are several methods for the preparation of nanocapsules
including nano-precipitation, emulsion–diffusion, tem-
plate-based method, double emulsification, emulsion-coa-
cervation, polymer-coating, and layer-by-layer (LbL).18–23
LbL, which was proposed by Sukhorukov and his co-
worker in 1998, is known as one of the most promising
techniques for nanocarrier formation. This method is based
on assembling multilayers, usually with the opposite
charges, on the surface of an organic or inorganic template
which will be removed by the use of etching procedures to
produce hollow capsules with multilayer shells.24,25
Recently, application of cyclodextrin (CD) and its deri-
vatives for the preparation of different types of nano-
systems has attracted lots of attention. β-cyclodextrins
(βCDs) are cyclic oligosaccharides consisting of α-(1–4)
inked- glucopyranose units that has a symmetrical form
resembling a truncated cone. The specific structure of βCD
with hydrophobic inner cavity and hydrophilic surface
makes it a promising candidate for drug delivery systems.
In fact, the inclusion complex formed between hydropho-
bic drugs as guests and the cavity of CD as the host is
widely used for drug delivery purposes. This feature not
only could be used for formulating hydrophobic drugs, but
could also be applied for production of supramolecular
structures like nanosponge and nanocapsules.26–28
Sulfadiazine (SDN) is a type of sulfonamide family, a
group of anti-bacterial and anti-fungal drugs with the
ability of infection treatment. SDN has a similar structure
with para-aminobenzoic acid, which is necessary for bac-
terial folic acid synthesis pathway and thus could stop the
synthesis procedure by inhibition of dihydropteroate activ-
ity. The low water solubility and chemical structure of this
drug make it a good candidate for interaction with the
hydrophobic cavity of βCDs. Moreover, due to its mole-
cular features, it can show a pH-responsive behavior.29–31
Based on the data mentioned above, in this research, it
is intended to fabricate a new pH-responsive polymeric
nanocapsule through the LbL method. For this purpose,
Fe2O3 nanoparticles were synthesized and covered with
Au nano-shell through Lyon’s method.32 Then, this core-
shell nanoparticle was used as a template for loading three
polymeric layers on its surface, which was done through
exploiting the inclusion complex formation between βCD
available in the first and the third layers and partially
hydrophobic SDN existed in the second layer. The first
layer consisted of thiolated βCD attached on the surface of
Au through self-assembly method. Polyacrylic acid (PAA)
conjugated with the SDN, as a pH-responsive agent, was
used as the second layer constituent forming inclusion
Zarepour et al Dovepress
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complexes with βCDs of the first layer. In the third layer,
βCD functionalized polyethylenimine was used to make
inclusion complex with remaining SDNs. The presence of
polymeric structure in the second and the third layer is
critical since they can maintain the structural sustainability
of the nanocapsule. At the final step, of nanocapsule fab-
rication, the Au shell was removed to prepare the whole
structure of the nanocapsule. Different types of character-
istic analysis (FTIR, UV-Visible spectroscopy, FE-SEM,
EDX, NMR, XRD, and Zeta potential) were conducted to
evaluate the successful synthesis of the nanocapsule. Then,
doxorubicin (DOX) as a hydrophilic, anti-cancer drug was
loaded into the nanocapsule and the drug loading and
release pattern of nanocapsule were assessed in response
to pH (7.4 and 6.6). At the end, the biocompatibility of the
nanocapsules (with and without drug) was evaluated by
cytotoxicity and hemocompatibility (coagulation, comple-
ment activation, and hemolysis) tests.
Materials and methods
Materials
FeCl2.4H2O and FeCl3.6H2O were purchased from Merck,
Germany. HAuCl4.3H2O, tetramethylammonium hydro-
xide (TMAOH), sulfadiazine, PAA (Mw=1800 g mol-1,
R & D application), (1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC), polyethylenimine
(PEI), Iodine, and potassium iodide were received from
Sigma, USA. 4-Dimethylaminopyridine (DMAP), sodium
borohydride, epichlorohydrin, sodium citrate, cystamine
dihydrochloride, hydroxylamine hydrochloride, dimethyl
sulfoxide (DMSO) and dimethylformamide (DMF) were
obtained from Merck, Germany. MCF-7 and L-929 cell
lines were purchased from Pasteur Institute of Iran,
Tehran, Iran.
Methods
Preparation of nanocapsule
Iron oxide synthesis
Fe3O4 nanoparticles were synthesized using the co-preci-
pitation method.33 Briefly, FeCl2.4H2O and FeCl3.6H2O
were dissolved in degassed HCl (0.4 M) and were then
rapidly added to 375 mL of ammonia solution (0.7 M).
The reaction solution should be mechanically stirred under
N2 atmosphere for about 30 mins at 45 °C by adjusting the
pH around 10. Then, the synthesized nanoparticles were
collected using neodymium magnet, washed several times
with deionized water (DI-water) and ethanol and dried
with freeze-dryer (VaCo5, Zirbus, Germany).
Maghemite nanoparticles were then synthesized by
oxidation of Fe3O4 nanoparticles. For this purpose,
Fe3O4 nanoparticles were sonicated in a solution of
HNO3 (0.4 M) for about 30 mins and then were refluxed
in HNO3 (0.04 M) at about 300 °C for 2 hrs. At the end,
the reddish-brown nanoparticles were collected by the
magnet, washed several times with DI-water and dried
by using freeze-dryer.32
Fabrication of Fe2O3@Au core-shell nanoparticles
Fe2O3@Au nanoparticles were synthesized based on Lyon’s
iteration method with little modifications.34 It should be
noted that Au has very low tendency to attach to the surface
of Fe; therefore iron oxide nanoparticles need a pre-treat-
ment step to be prepared for coating with Au shell. For this,
the nanoparticles were dissolved in a solution of TMAOH
(0.1 M) for at least one night in a concentration of about
36 mM. Then, a diluted solution of nanoparticles (1.1 mM)
was mixed with the same amount of sodium citrate (0.1 M)
for about 20 mins. After that, this solution was diluted 20
fold with the addition of DI-water and TMAOH and then
different amounts of NH2OH·HCl, 0.2 M (750, 250, 250,
250, 250 μl) and HAuCl4, 1% (625, 500, 500, 500, 500 μl)
were added to this solution during five consecutive itera-
tions with 30 mins interval times.
Synthesis of the first polymeric layer (L1)
The first polymeric layer was consisted of a specific amount
of thiolated-βCD (βCDSH) polymerized on the surface of
Fe2O3@Au nanoparticles. The βCDSH was produced in a
two-step mechanism; at first, βCDs were tosylated using
para-toluenesulfonyl chloride to achieve mono-6-tosyl-β-
cyclodextrin. In detail, 2 gr of βCDs were dispersed in
28 mL DI-water, then 6 mL of NaOH solution was added
drop-wise to dissolve the βCD. The tosylation reaction was
occurred during a 5 h interaction between the above solu-
tion and para-toluenesulfonyl chloride (500 mg). The final
solution was filtered to remove non-reacted tosyl reagents,
and tosylated-βCDs (Tos-βCDs) were separated by the addi-
tion of cationic resins in ice-bath.35
At the next step, Tos-βCDs were reacted with cysta-
mine dihydrochloride in a mixed solution of water: DMSO
(1:1), at 70 °C for 72 h. The results of this reaction were
exposed to 1ml of sodium borohydride (2.6 mmol) that
reduced the disulfide bond of the cystamine and produced
βCDSH (Scheme 1).36,37
Dovepress Zarepour et al
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The monomeric βCDSH species were then attached to
Fe2O3@Au nanoparticles through a self-assembling reac-
tion during 24 h at room temperature. Then, the polymer-
ization reaction was conducted on the surface of
nanoparticles using epichlorohydrin as the cross-linker.
The final product was separated by the magnet, washed
with DI-water and dried by freeze-dryer.
Synthesis of the second polymeric layer (L2)
The second polymeric layer contained a pH-responsive
reagent which could form host-guest interactions with βCD.
It was prepared through a mediation reaction between SDN
and PAA with the aim of EDC/DMAP as coupling agents.
Briefly, 1 mmol of PAAwas dissolved in 40 mL DMF. After
10 min, SDN (8 mmol) was added to the mentioned solution,
DMAP (1.5 mmol) and EDC (3 mmol) were then added with
about 15 mins interval time, respectively. The final solution
was stirred for about 48 h at room temperature, precipitated
in water and dried after washing several times with DI-water.
Synthesis of the third polymeric layer (L3)
In the third layer, the linear form of polyethylenimine (L-PEI)
was used as a backbone for the attachment of βCDs. For this, 4
gr of Tos-βCD was reacted with the amine groups of polymer
L-PEI (500 mg) in 36 mL DMSO for seven days. The final
product was precipitated in the presence of excess amounts of
acetone and dialyzed against water for another seven days to
remove non-reacted components.37
Fabrication of self-assemble nano-system
To prepare the nano-system, an aqueous solution of
Fe2O3@Au/PβCD nanoparticles was added dropwise to the
solution of L2 in DMSO, and the final reaction mixture was
magnetically stirred for 2 days. Then, the nanoparticles were
collected by a magnet, washed with DI-water to remove
unreacted materials, and after 2 h keeping in −20 °C, dried
with freeze-drier to tight the reaction of βCDs and SDNs. In
the next step, an aqueous solution of Fe2O3@Au/PβCD/
PAA-SDN was added to the aqueous solution of PEI-βCD,
dropwise, stirred for 48 h and dried the same as described for
the previous step.38
Au layer removal
Finally, the nanocapsule was prepared through the Au
layer removal using a solution of potassium iodide and
extra amounts of iodine in water.39 Using excess amounts
of iodine prevented the decomposition of unstable gold
iodide. The Au depleted nanocapsules were then separated
by a magnet, washed several times with DI-water to
remove excess iodine and dried with freeze-dryer.
Characterization
Different types of physicochemical analysis were used to
characterize the nanocapsule in the different fabrication
steps. FTIR spectroscopy (400–4000 cm−1) was chosen to
evaluate the surface characteristics of each layer and also
inclusion complex formation (JASCO 6300 spectroscope,
Scheme 1 Two step production of βCDSH.
Zarepour et al Dovepress
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Japan, transmission mode). The crystalline structure of nano-
particles and host-guest interaction were evaluated by XRD
(Bruker diffractometer with Cu Kα radiation, Germany). To
assess the effect of each Au addition iterations on shell forma-
tion, UV-Visible spectroscopy (V670, Japan) was utilized.
Size, morphology, and elemental composition of the nanocap-
sules were determined by FE-SEM/EDX (MIRA3 TESCAN,
Czech Republic). In addition, H-NMR (Bruker Ultrasheet-
400 MHz Spectrometer, Germany) was selected to confirm
the production of polymeric layers. The charge of the nano-
system after the addition of each layer was also assessed by
Zeta potential (HORIBA, scientific SZ100, Japan).
Drug loading determination
DOX is a typical hydrophilic drug that is widely used for the
treatment of various types of cancers. It can affect the cancer
cells by intercalating the nucleus DNA through blocking
gene replication and transcription. The rapid elimination of
the drug from the body, as well as its nonreversible side
effects, shed light on the importance of using nanocarrier
for its delivering to the targeted site.40,41
DOX loading was done in three different mass ratios of
drug (D): nanocapsule (N) (2:1, 1:1 and 1:2) in phosphate
buffer saline (PBS) in two different pH (6.6 and 7.4). After
24 h of drug exposure with nanocarrier at room tempera-
ture, the loaded nanocarriers were collected with a magnet,
washed with PBS to remove unloaded drugs and dried
with freeze-dryer.
The amount of unloaded drug was determined by mea-
suring the absorbance of the supernatant at 490 nm using
UV-Visible spectrophotometer, then the percentage of
loading and entrapment efficiency of the drug were calcu-
lated based on Equation (1) and (2), respectively:42
% Loading Efficiency LEð Þ ¼
Total DOX added wtð Þ  Unloaded DOX wtð Þ
Total nanocarrier wtð Þ (1)
%Entrapment Efficiency EEð Þ ¼
Total DOX added wtð Þ  Unloaded DOX wtð Þ
Total DOX added wtð Þ (2)
Ph-responsive drug release
The pH-responsive release profiles of selected drug-loaded
nanocapsules were assessed at 37 °C during 14 days. For
this purpose, specific amounts of drug-loaded nanocap-
sules were dispersed in 1.5 mL PBS with two different
pH of 7.4 and 6.6, which were selected based on the
normal pH of the body and pH of tumor tissues,
respectively.43 After an appropriate time, nanocapsules
were collected by a magnet, and the amounts of drug
released were determined by comparing the absorbance
of the supernatant with the standard curve.
Biocompatibility tests
MTT assay
The cytotoxicity of the nanocapsules (with/without drug
molecules) was evaluated by MTT assay. For this purpose,
MCF-7 and L929 cells were selected as cancerous and nor-
mal cell lines, respectively. Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) medium in 96 well plates
with the concentration of 10,000 cells per well and incubated
for 24 h in 4.5% CO2 atmosphere at 37 °C. After that,
different concentrations (0.1, 0.2, 0.3, 0.4 and 0.5 μg mL−1)
of drug-loaded nanocapsules in media were exposed to cells
for 24 and 48 h. Moreover, specific amounts of free drugs (as
positive control) and nanocapsule (without drug) were also
subjected to the cells. After 24 and 48 h, the medium of each
well was discarded, cells were washed with PBS and then
100 μl of fresh media with 10 μl MTTsolution (5 mgmL−1 in
PBS) was added to each well. After 4 h incubation at 37 °C,
the supernatant of each well was replaced with 100 μl DMSO
and cells were incubated for another 1 h. During this process,
the MTT salt was converted to an insoluble component,
formazan, via an enzymatic reaction done in the mitochon-
dria of the living cells. The produced formazan was then
solubilized by the addition of DMSO and the absorbance of
each well was determined at 493 nm using ELISA reader
(Bio-Rad, USA).
Hemolysis assay
To evaluate the hemolytic effect of nanocapsules (with/
without drug) on the red blood cells (RBCs), 3 mL of the
blood sample in EDTA-contained tube (from a volunteer
with ethical permissions) was centrifuged for 5 mins at
1600 RPM to separate the RBCs from other parts of the
blood. The precipitate RBCs of the blood sample were then
washed three times with PBS and centrifuged to remove
any hemolytic contaminant. Then, 200 μl of the sedimented
RBC was dispersed in 3.8 mL of PBS. After that, 200 μl of
this solution was added to 800 μl of nanocapsule solution
(with different concentrations). DI-water and PBS were
used as positive and negative controls, respectively. The
samples were kept at room temperature for about 3 h and
then were centrifuged at 1600 RPM for 5 mins. The absor-
bance of the supernatant was measured at 541 nm and the
amount of hemolysis was calculated using Equation 3:44
Dovepress Zarepour et al
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% of Hemolysis ¼
Absorbance of sample Absorbance of negative control
Absorbance of positive control Absorbance of negative control
(3)
Complement activation
The complement system is a part of the immune system
contains at least 35 proteins that can be stimulated in response
to any foreign material that enters the body and eliminates it
through three main pathways: classical, alternative and lectin
route. Stimulation of each of these systems can limit the
foreign materials through the attachment of these proteins on
the surface of the material or/and by activating the opsonins of
the immune system.45 Two main components of this system
that are evaluated in blood tests are C3 and C4 proteins. Based
on this, in this research, different concentrations of nanocap-
sules (with/without drug) were exposed to blood plasma and
their effects on the activation of C3 and C4 proteins were
evaluated by using a commercial single radial immunodiffu-
sion (SRID) immunoassay kit.46
Coagulation assay
Coagulation is one of the other eliminating mechanisms of
the immune system for the foreign materials in which the
activation of a cascade of several factors through two main
intrinsic and extrinsic pathways will lead to cross-linked
fibrin clot formation. Based on this, here the effect of the
nanocapsules on the intrinsic and extrinsic pathways of the
coagulation system was evaluated by quantitative measure-
ment of the change in the prothrombin time (PT) and acti-
vated partial thromboplastin time (APTT). To this end,
specific amounts of platelet poor plasma were exposed to
different concentrations of nanocapsules (with/without drug)
and were incubated at 37 °C for about 30 mins. Then the
activation time was measured after addition of Innovin (as
the activator of extrinsic pathway), and actin and calcium
chloride (the activators of intrinsic pathways).47
Statistical analysis
SPSS software (version 21, parametric analysis of variance
[ANOVA (Tukey)]) was used for quantitative data analysis
and results are reported as mean values ±standard devia-
tion (SD) with significant value at P≤0.05.
Results
Fabrication of iron oxide nanoparticles
Monodispersed maghemite nanoparticles were synthesized
by oxidation of Fe3O4 nanoparticles. For this purpose, the
Fe3O4 nanoparticles were oxidized in the presence of diluted
nitric acid that led to the preparation of reddish-brown nano-
particles from the primary black ones. The fabrication of
magnetic nanoparticles was confirmed by using different
analytical tests. The FE-SEM result of γ-Fe2O3 is shown in
Figure 1. It is evident from the figure that the γ-Fe2O3
nanoparticles have monodispersed spherical shape with 19
±2 nm size. Moreover, the formation of γ-Fe2O3 nanoparti-
cles was also evaluated by using other techniques such as
FTIR and XRD, the result of which are reported in the
supporting information as Figures S2 and S3.
Synthesis of fe2o3@au core-shell
nanoparticles
For preparation of Au coated Fe2O3 nanoparticles, a solution
of 1.1 mM γ-Fe2O3 wasmixedwith sodium citrate for at least
20 mins. During this process, the activated surface of the iron
oxide nanoparticles was modified with citrate groups that act
as a thin layer coating on the surface of magnetic nanoparti-
cles to prepare them for Au reception, as well as, being a
critical reagent for the Au shell reduction process. After
dilution of the above solution, HAuCl4.3H2O in combination
with the reducing agent (NH2OH·HCl) was added in five
iterations resulting in the fabrication of a thick shell on the
surface of nanoparticles. By addition of the first iteration, the
color of the solution changed from light brown to dark purple
(Figure 2A) confirming the production of Au nanoparticles.
In the first iteration, the prepared Au nanoparticles were most
likely deposited on the surface of the nanoparticles in an
Figure 1 FE-SEM analysis of γ-Fe2O3.
Zarepour et al Dovepress
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island pattern which was then converted to a complete shell
by proceeding of the next iterations. This feature was con-
firmed by the results of UV-Visible spectroscopy in which a
blue shift was observed after the addition of each iteration
(Figure 2B). In other words, the blue shift of the UV-Visible
spectrum revealed that the morphology of the coated nano-
particles was gradually changed to a uniform spherical shape
during each addition, a phenomenon that also could be
approved by a significant decrease in the broadening of the
peaks.48
The spherical shape of the core-shell nanoparticles was
also confirmed through the result of FE-SEM imaging. As it
is shown in Figure 3A, coating Au on the surface of nano-
particles turned to decrease the aggregation of the nanopar-
ticles and resulted in nanoparticles with mean size of 36
±4 nm. Moreover, the chemical composition of the template
was assessed by Energy Dispersive X-ray (EDX) spectro-
scopy. The presence of Au and Carbon atoms confirmed the
gold coating on the surface of iron oxide nanoparticles
(Figure 3B). The successful coating of magnetic nanoparti-
cles with Au shell was also revealed by the crystal structure
of the nanoparticles (XRD) (Figure 3C), in which peaks at
around 45°, 52°, 77° and 93.5° could be indexed to (111),
(200), (220) and (311) planes of gold cubic and weak peaks at
36°, 42°, 51° and 75° could be indexed to (200), (311), (002)
and (102) planes of γ-Fe2O3 (based on Joint Committee on
Powder Diffraction Standards, JCPDS 04–0784 and JCPDS
39–1346, respectively).49
Preparation of nanocapsule
As mentioned previously, the nanocapsules were con-
sisted of a template with three polymeric layers. In the
first layer, βCDSH components were attached on the
surface of the Au shell through self-assembly driving
force and then, they were polymerized using epichlor-
ohydrin. During the polymerization reaction, the chlor-
ine atom of the epichlorohydrin acts as a leaving group
and by the interaction with the activated hydroxyl group
of βCD, leads to the formation of a connection between
βCD and epichlorohydrin through the ether bond. In the
second step of this reaction, a ring-opening polymeriza-
tion reaction occurred between the other side of epi-
chlorohydrin and one another βCD component. The
cascade reaction happened between the available
Figure 2 (A) Changing the solution color before and after of Au addition, (B) UV-Visible spectroscopy of five Au iterations.
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βCD components and epichlorohydrin, leads to the pro-
duction of a polymeric chain around the γ-Fe2O3@Au
nanoparticles.50
The SDN functionalized PAA was selected as the sec-
ond layer that was prepared through an amidation reaction.
For this purpose, excess amounts of SDNs were exposed
to the carboxyl groups of PAA in the presence of EDC and
DMAP. Then, the inclusion complex between PAA-SDN
and βCDs of the Fe2O3@Au/PβCD was formed within
72 h using the freeze-drying method.51 In this process,
the amino-hexagonal ring and the NH group of the SDN
interact with the hydrophobic cavity of βCD (Scheme 2).
Changing the pH of the surrounded environment induced a
positive charge in this NH group leading to a partial
exclusion of SDN from the cavity.
For the third layer, L-PEI polymer functionalized with
βCDs was chosen. The attachment of PEI to Tos-βCDs
was performed with the aim of EDC and DMAP. The as-
prepared L3 layer was loaded on the γ-Fe2O3@Au/PβCD/
PAA-SDN by using the freeze-drying method. Finally, the
hollow nanocapsule was prepared by removing the Au
core of the nano-system in the presence of a solution of
KI and I2. The first significant change that revealed the Au
deletion was the color change of the samples from dark
purple to light brown (Figure 4).
Characterization
Several types of physicochemical analysis were used to
assess the fabrication of the nanocapsule and its compo-
nents. The results of characterization tests of the polymeric
layers can be found in supporting information (Figures
S1-S6).
FTIR
Figure 5A shows the FTIR result of βCD polymerized on
the surface of the γ-Fe2O3@Au template. The main differ-
ence between polymerized βCD and βCD alone is the
presence of two peaks in the range of 2800–2900 cm−1
Figure 3 (A) FE-SEM, (B) EDX and (C) XRD of γ-Fe2O3@Au core-shell nanoparticles.
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in the spectrum of polymerized βCD compared with one
peak in the spectrum of βCD alone. Moreover, distinctive
changes have occurred in the peaks mode of polymerized
βCD in the range of 1200–1300 cm,−1 which are asso-
ciated to the CH stretching and bending vibrations. The
other characteristic peaks in this curve are peaks at around
3400, 1040 and 580 cm−1 that are attributed to the OH and
C-O-C stretching vibrations of polymerized nanoparticles,
and Fe-O bond of γ-Fe2O3, respectively.
52 Moreover, the
characteristic peak of thiol group at around 2550 cm−1 is
also removed, which could confirm the successful attach-
ment of βCDs on the surface of Au through a self-
assembled monolayer bond.
By the addition of the second layer, the inclusion
complexes between βCDs of the first layer and SDNs of
L2 were formed that was confirmed by the results of FTIR.
For this, a comparison study was done between the curves
of γ-Fe2O3@Au/PβCD, γ-Fe2O3@Au/PβCD/PAA-SDN,
L2 and physical mixture of the L2, and γ-Fe2O3@Au/
PβCD (Figure 5B). The FTIR spectrum of γ-Fe2O3@Au/
PβCD/PAA-SDN has significant differences to that of
γ-Fe2O3@Au/PβCD. In other words, the peaks at around
1690, 1640, 1450, 1370 and 1240 cm−1 which emerged in
the spectrum of γ-Fe2O3@Au/PβCD/PAA-SDN, can be
attributed to the amide bond, benzene ring, methyl groups
and S=O groups of the L2 layer, respectively. The
appearance of Fe-O peak and also the redshift in
the spectrum of γ-Fe2O3@Au/PβCD/PAA-SDN are the
differences of this component with L2. Finally, in compar-
ison to the physical mixture, the intensity of the whole
peaks of the γ-Fe2O3@Au/PβCD/PAA-SDN is dramati-
cally decreased. Moreover, there are some peaks in the
spectrum of the physical mixture, which are attributed to
the βCD of the first layer and are disappeared in the γ-
Fe2O3@Au/PβCD/PAA-SDN spectrum. Another critical
point in the spectrum of γ-Fe2O3@Au/PβCD/PAA-SDN
is the reduction of CN, aromatic amine and S=O peaks
of SDN in comparison to the L2 and physical mixture that
can be attributed to the formation of inclusion complex.
As it was described previously, the interaction of the third
layer with γ-Fe2O3@Au/PβCD/PAA-SDN occurred through
inclusion complexation between βCDs of the third layer and
the remaining SDN. The FTIR results of γ-Fe2O3@Au/PβCD/
PAA-SDN/PEI-βCD, γ-Fe2O3@Au/PβCD/PAA-SDN, L3,
and physical mixture of γ-Fe2O3@Au/PβCD/PAA-SDN and
L3 are shown in Figure 5C. As can be seen in this figure, the
spectrum of γ-Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD fol-
lows the pattern of PEI-βCD with some slight differences
that distinguish it from the spectrum of the L3 and physical
mixture. These differences include the presence of a Fe-O
peak at around 580 cm−1 in the γ-Fe2O3@Au/PβCD/PAA-
SDN/PEI-βCD curve and also a significant decrease in the
intensity of the peaks. Moreover, the existence of βCD peaks
at around 1250–1000 and 1650 cm−1 in the γ-Fe2O3@Au/
PβCD/PAA-SDN/PEI-βCD spectrum, differentiate it from γ-
Fe2O3@Au/PβCD/PAA-SDN spectrum. All these findings
confirmed the fabrication of γ-Fe2O3@Au/PβCD/PAA-SDN/
PEI-βCD from the interaction between L3 and γ-Fe2O3@Au/
PβCD/PAA-SDN.
Finally, by removing the Au core, a significant increase
occurs in the intensity of the whole curve. Moreover, by
the elimination of Au from the core of the nano-system,
the characteristic peaks of L2 and L3 layers and also Fe-O
Scheme 2 The formation of an inclusion complex between βCD and SDN.
Figure 4 Change in the color of nano-system before and after removing the Au.
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Figure 5 FTIR results of (A) γ-Fe2O3@Au/PβCD (B) γ-Fe2O3@Au/PβCD, γ-Fe2O3@Au/PβCD/PAA-SDN, physical mixture, PAA-SDN, (C) γ-Fe2O3@Au/PβCD/PAA-
SDN, γ-Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD, physical mixture, PEI-βCD, and (D) nanocapsule.
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peaks of γ-Fe2O3 available in the core of nanocapsule are
prominently increased (Figure 5D).
XRD
The probable differences in the crystallographic structure
of nano-systems after the addition of each layer were
investigated using XRD. By comparing the XRD result
of γ-Fe2O3@Au/PβCD with that of γ-Fe2O3@Au, the
polymerization of CD on the surface of nanoparticles
was confirmed. In fact, a significant shift in the peaks of
Au and Fe to the lower angles occurred in the spectrum of
the γ-Fe2O3@Au/PβCD, so that the peaks which were
attributed to the index planes of (111), (200), (220), and
(311) of Au and (200), (311), and (102) of Fe showed a
shift of about 7° to the lower degree. Moreover, an appar-
ent reduction in the intensity of Fe and Au peaks, deletion
of some Fe peaks and also the appearance of a broad peak
in the range of 2θ=10–20°, which is appeared due to the
amorphous structure of polymeric layer, could confirm the
polymerization of βCD on the surface of nanoparticles
(Figure 6A).
The preparation of inclusion complex was evaluated by
comparing the XRD patterns of the γ-Fe2O3@Au/PβCD/
PAA-SDN with PAA-SDN, γ-Fe2O3@Au/PβCD, and their
physical mixture. The XRD pattern of PAA-SDN shows
amorphous peaks at around 2θ=10–20° and 2θ=25–35°.53
γ-Fe2O3@Au/PβCD/PAA-SDN has similar XRD pattern
with the pattern of γ-Fe2O3@Au/PβCD except that in the
spectrum of γ-Fe2O3@Au/PβCD/PAA-SDN the Fe index in
2θ=32° (200) is disappeared. This is an indicating difference
between this sample and γ-Fe2O3@Au/PβCD and physical
mixture, which suggests that this is due to the presence of
PAA-SDN peak in this reign. Moreover, the presence of Au
peaks in this spectrum in comparison to the PAA-SDN,
confirmed the correct reaction between γ-Fe2O3@Au/PβCD
and L2 layers (Figure 6B).
In Figure 6C, the XRD pattern of the nano-system after
the addition of the third layer is compared with γ-
Fe2O3@Au/PβCD/PAA-SDN, L3, and their physical mix-
ture. By the addition of the third layer to the nano-system,
the PAA polymeric peak at around 2θ=10–20° disap-
peared. Moreover, it could be seen that there are differ-
ences between the diffractograms of γ-Fe2O3@Au/PβCD/
PAA-SDN/PEI-βCD, L3 and γ-Fe2O3@Au/PβCD/PAA-
SDN, suggesting the attachment of L3 on γ-Fe2O3@Au/
PβCD/PAA-SDN. Existence of difference between the
curve of physical mixture and the third layer technically
could reveal the inclusion complex formation. It is
necessary to mention that the several peaks exist in the
spectrum of L3 and physical mixture is attributed to the
NaCl that was used in the purification step of the L3 layer.
However, these peaks disappeared in the spectrum of γ-
Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD due to the multiple
washing steps before freeze-drying the sample.
Zeta potential analysis
The effect of each layer on the charge of the nano-systemwas
evaluated by Zeta potential measurements (Table 1). The
results revealed a positive charge for γ-Fe2O3 nanoparticles,
which is due to the presence of HNO groups that were used
for converting Fe3O4 to Fe2O3. Addition of Au shell changes
the positive charge of the nano-system to negative because of
the attendance of carboxylic acid groups of citrate. After
addition of the first layer, the charge is dramatically
decreased and reaches to about −39 mV, which could be
attributed to the several hydroxyl groups of βCD moieties.
By the addition of the second layer to the nano-system, the
charge of the samples gets more negative value. The inclu-
sion complex between βCD and SDN masks the nitrogen
groups of SDN, which in turn could show positive charge
before this complex; thus, the negative charges of the SO
groups of SDN lead to the nano-system charge change to
more negative charges. Finally, by addition of the third layer,
which has several βCD components with large amounts of
hydroxyl groups, the charge of nano-system gets more nega-
tive. These changes in charge of the nano-system after addi-
tion of different layers could be considered as evidence that
confirmed the successful preparation of nanocapsule.
FE-SEM analysis
Changes in the size and morphology of the nano-system
during the synthesis process were assessed using FE-SEM.
Based on the results of Figure 7, nanoparticles have a sphe-
rical shape with the mean size 35.5±0.2, 40±2, 44±1.5 and 43
±1.5 nm for γ-Fe2O3@Au/PβCD (Figure 7A), γ-Fe2O3@Au/
PβCD/PAA-SDN (Figure 7B), γ-Fe2O3@Au/PβCD/PAA-
SDN/PEI-βCD (Figure 7C), and hollow nanocapsules
(Figure 7D), respectively.
EDX
Changes in the chemical composition of nanocapsule dur-
ing the synthesis process were investigated by using EDX
spectroscopy. The advent of sulfur and nitrogen peaks in
the EDX diagram along with an increasing amount of
carbon and oxygen atoms confirms the attachment of
βCDSH on the surface of nanoparticles (Figure 8A). By
the addition of the second and third layers, the amount of
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sulfur and nitrogen are also increased, confirming the
presence of these layers in the sample (Figure 8B, C).
Preparation of the hollow nanocapsule is accompanied by
a significant reduction in the peaks of Au and also a
dramatic increase in the peaks of Fe (Figure 8D).
Determination of loading and entrapment
efficiency
Doxorubicin, as a widely used anti-cancer drug, was cho-
sen and the loading behavior of the nanocapsule in
response to changes to the pH of the surrounding
Figure 6 The XRD results of (A) γ-Fe2O3@Au/PβCD, (B) γ-Fe2O3@Au/PβCD, PAA-SDN, γ-Fe2O3@Au/PβCD/PAA-SDN, physical mixture of γ-Fe2O3@Au/PβCD and
PAA-SDN and (C) γ-Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD, γ-Fe2O3@Au/PβCD/PAA-SDN, PEI-βCD and physical mixture.
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environment was assessed. For this purpose, three differ-
ent mass ratios of the drug to nanocapsule were dispersed
in PBS in two different pH (6.6 and 7.4). The results of
drug loading after 24 h are described in Table 2 confirming
the effect of pH on drug loading efficiency of the nano-
capsule. Based on the results, the amounts of drugs loaded
at normal pH are more than the acidic one. Moreover, by
increasing the mass ratio of drug to nanocapsule, the
loading efficiency is increased significantly so that in
sample 3 and normal pH, it reaches to about 160% reveal-
ing an extraordinary capacity of this nanocapsule for drug
loading of DOX.
The addition of drug molecules to the nanocapsule also
leads to a dramatic increase in charge of nanocapsule from
−42.8 to −28.9 (Figure 9) which is due to the positive
charge of the drugs.
pH-responsive drug release
The pH-responsive drug release behavior of the nanocap-
sule was investigated in PBS with two different pH (7.4
and 6.6) at 37°C in three different mass ratios. After
specific time intervals, the solution of each sample was
replaced with a fresh solution, and the absorbance of each
solution was read at 490 nm to determine the amount of
released drug. The results of drug release are shown in
Table 1 Charge variation of the nano-system by addition of
different layers
Nanomaterial Charge (mV)
Fe2O3 34.5
Fe2O3@Au −11.6
Fe2O3@Au/PβCD −38.9
Fe2O3@Au/PβCD/PAA-SDN −40.3
Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD −42.3
Figure 7 FE-SEM result of (A) γ-Fe2O3@Au/PβCD, (B) γ-Fe2O3@Au/PβCD/PAA-SDN, (C) γ-Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD and (D) nanocapsule.
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Figure 10 (A–C). It can be recognized that all three sam-
ples show a pH-responsive behavior in their releasing
pattern. Moreover, the release process follows a sustained
release pattern so that drug release could be accomplished
even after 14 days.
Based on the results, the most significant difference
pH-responsive behavior is attributed to the sample 1
(Figure 10A) with about 74% drug released in acidic pH
and about 33% in the normal condition during 14 days,
which can be due to the presence of the low amount of
drug molecules in this sample. In other words, the smaller
amount of drug molecules in this case, not only turns to
reduce the competition between the drug molecules, but
also they are distributed in a larger volume of nanocapsule,
and thus could be released in a more controllable state.
By increasing the amounts of entrapped drugs, the
competition between drug molecules is increased;
Figure 8 EDX analysis of (A) γ-Fe2O3@Au/PβCD, (B) γ-Fe2O3@Au/PβCD/PAA-SDN, (C) γ-Fe2O3@Au/PβCD/PAA-SDN/PEI-βCD and (D) Nanocapsule.
Table 2 Entrapment efficiency (EE) and the loading efficiency (LE) percentage of drug in nanocapsule at two pH with different mass
ratios
Nanocapsule to Drug (N:D) Sample 1 (N2:D1) Sample 2 (N1:D1) Sample 3 (N1:D2)
pH 6.6 %EE 74.31 85.55 76.67
%LE 37.48 85.55 153.33
7.4 %EE 85.50 90.91 79.40
%LE 42.75 90.91 158.80
Abbreviations: N, nanocapsule; D, drug.
Figure 9 Zeta potential curve of nanocapsule with drug.
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preventing the burst release of drugs, as well as increasing
the time of drug released (sample 2 (Figure 10B), and
sample 3(Figure 10C)). Although these two samples have
longer release time, the amounts of the released drug
during 14 days, are the same or even higher than that of
sample 1, which implies that they could show their toxicity
effect during a more extended period of the time.
The other important point about this nanocapsule is that it
shows an on/off switching behavior during the pH-respon-
sive drug release. In other words, by changing the pH of the
surrounding environment from normal to acidic, the SDNs
located inside the cavity of cyclodextrin components par-
tially exit, so the distance between three layers are increased,
leading to an increase in the released drug in this acidic pH.
Figure 10 In vitro release profile of doxorubicin from (A) Sample, 1, (B) Sample 2 and (C) Sample 3, in PBS in two different pH 7.4 and 6.6.
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Biocompatibility tests
Based on the results of drug release, sample 1 and sample
3 were selected to evaluate the biocompatibility of the
nano-system using different types of tests including MTT
assay as cell viability assessment and hemolysis, coagula-
tion and complement activation tests as hemocompatibility
discernment.
MTT assay
One of the most critical tests that should be done before an
in vivo application of a nano-system is the cell viability
test to determine the cytotoxicity effect of the system.
MTT assay, as one of the most common methods that is
used for this purpose, is based on converting the MTT salt
to an insoluble component, formazan, through a mitochon-
drial enzymatic reaction which is only carried out by
living cells.54
The results of MTT assay of different nanocapsule con-
centrations (with/without drug) on MCF7 and L929 cell
lines after 24 and 48 h are shown in Figure 11(A, B).
These results show that the drug-loaded nanocapsules
have no significant effect on normal cells, even after 48 h
(Figure 11A), while they show cytotoxicity against cancer
cells after 48 h at concentrations of 0.4 and 0.5 μg mL−1 of
sample 1 and concentrations above 0.2 μg mL−1 of sample 3
(Figure 11B). This is due to the changes that occurred in the
pH of the cancer cell media, which is originated from their
intrinsic property. In fact, cancer cells use the lactic acid
pathway for creating ATP molecules that lead to change in
the intracellular pH from normal to acidic form. These cells
preserve their normal pH by excluding H+ ions to the
extracellular environment through specific ion-exchange
channels that turn to the preparation of a low acidic micro-
environment around the cells which can provide the best
condition for the drug release from nanocapsule. It is neces-
sary to mention that the higher amounts of drug released
from sample 3 is the reason for the difference between the
effective concentration of this sample and sample 1.
The cytotoxicity of nanocapsule without the drug (in the
concentration of about 0.5 μg mL−1) was also tested and
Figure 11 Results of MTT assay on (A) L929 and (B) MCF-7 cell lines (*P≤0.05).
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showed no cytotoxicity effect on the cells, revealing the
cytocompatibility of the nanocapsule alone. Furthermore,
the cytotoxicity of drug-loaded nanocapsule was compared
with the free drug (with the same concentrations as the
lowest and the highest amount of drug-loaded in the nano-
capsule), and the results show the same cytotoxicity prop-
erty as the loaded one. The results of this test were
evaluated by statistical analysis (SPSS), and the significant
samples are determined by “*” in the figures.
Based on the results of this test, the pH-responsivity of
the nanocapsule could be confirmed by the appearance of
cytotoxicity in cancer cells. Moreover, a brief comparison
between the IC50 values of sample 1 and sample 3 (2 μM
and 3μM, respectively) with that of free drug (9.8 μM),
revealed that this nano-system shows an improvement in
the therapeutic drug efficacy of doxorubicin.55
Hemolysis assay
The hemolytic behavior of the nanocapsule was evaluated
by using hemolysis assay. For this purpose, different con-
centrations of sample 1 and 3 (0.1, 0.2, 0.3, 0.4 and 0.5)
were exposed to RBC for a specific time, and then the
percentage of hemolysis of each sample was determined
by UV-Vis spectrophotometer. Both of the samples show
the hemolytic activity of less than 1 percent (Figure 12),
revealing that they have no hemolytic effect on RBC and
thus it could be considered that they are hemocompatible
(according to the American Society for Testing and
Materials (ASTM F 756–00, 2000)).56,57
Complement activation
Evaluation of the complement activation, as part of the
immune system, is one of the most important analysis for
biomedical use of nano-systems. C3, C4, and C5 are the most
common components of this system that are usually assessed
for determining the effect of foreign materials on comple-
ment activation. Herein, the drug-loaded/non-loaded nano-
capsules were exposed with blood plasma and their effect on
the activation of C3 and C4 were assessed by using specific
kits. Results demonstrated that neither the drug-loaded nano-
capsules nor the nanocapsules alone show no significant
effect on the activation of complement components, which
could confirm their hemocompatibility (Figure 13(A, B)).
Statistical analysis also showed no significant differences
between these samples compared to the control (p≤0.05).
Coagulation assay
The body uses several approaches for limiting foreign
materials and removing them from the circulation system,
one of which is clot formation that could be stimulated by
activation of two main pathways; extrinsic and intrinsic.
The effect of nanocapsules on these pathways was deter-
mined by calculating the prothrombin and thromboplastin
activation time (PT and APTT) of platelet poor plasma.
Results of coagulation assay (Figure 14(A, B)) confirmed
that nanocapsules (with/without drug components) have no
effect on the activation time of coagulation pathways and
thus could be considered hemocompatible. The results of
statistical analysis show no significant differences between
the samples and the control (p≤0.05).
Discussion
Utilizing biological stimuli responsive manners have
become one of the most important approaches for fabrica-
tion of therapeutic nano-systems, in particular nanocarriers
for cancer drugs. These nanocarriers could deliver and
release drug molecules just in the tumor tissue using an
on/off switchable method. This means that they can selec-
tively “switch on” in targeted cells and “switch off” in
Figure 12 Hemolysis results of sample 1 and sample 3.
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other tissues, and thus eliminating the toxic effects of
drugs on healthy cells.58
Among different types of biological stimuli approach,
pH-responsiveness is one of the most commonly studied
functionalities for cancer therapy. In other words, the
apparent differences between pH of cancer tissues in com-
parison with healthy texture is potentially a suitable trigger
for the fabrication of proprietary drug delivery systems.59
Cancer cells are reprogramming uncontrolled cells that
use anaerobic metabolic pathway for the production of
ATP molecules even in the presence of oxygen. This
change in the energy production pathway is an intelligent
tactic employed by cancer cells to convert the glycolytic
intermediates through specific approaches into the various
types of biological macromolecules like nucleosides and
amino acids to facilitate the production of organelles and
macromolecules needs for the new cells. The anaerobic
metabolism often encountered in cancer cells is accompa-
nied by an increase in the amounts of lactic acid
concentration in the cells, ultimately leading to extracel-
lular tumor acidosis. It means that cancer cells maintain
their normal intracellular pH (7.4) by excreting the excess
protons to the extracellular matrix through the upregula-
tion of several proton extrusion mechanisms and thus the
extracellular microenvironment of the cancer cells is
slightly acidic (6.5–7).60,61
Based on this difference in pH of cancer and healthy
tissues, different types of pH-responsive nano-systems are
introduced which can respond to the pH change by using
cleavable linkers or through applying the charge conver-
sion components.62
Based on this feature of the cancer tissues, in this
research, a smart pH-responsive nano theranostic capsule
with a mean size of about 43 nmwas fabricated for delivering
anti-cancer drugs. This nanocapsule is constructed based on
the supramolecular structure of CD molecules that contains
three polymeric layers which are located around themagnetic
core of the nano-system. This magnetic core also donates a
Figure 13 Effect of different concentrations of nanocapsule on (A) C3, (B) C4.
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diagnostic feature to this nano-system. This is a new type of
supramolecular structure with a high capacity for drug load-
ing and also shows on/off switching drug release behavior
which is originated from the inclusion complex between
cyclodextrin components and SDNs. This nano-system
could show a hydrogel-like behavior, and release its cargos
in a swelling like manner in acidic pH without losing its
structural framework.
As it has been mentioned before, use of stimuli agents
in the structure of nano-platforms, induces on/off switch-
ing behavior, which implies that these types of drug deliv-
ery systems could release their component just in the
presence of a specific situation. The presence of the stimuli
situations, turns to a change in the structure of the nano-
system that leads to release the drugs entitled ”switch on”,
while by removing that situation no release occurs from
the nano-system, which is entitled “switch off”. These
nanocarriers are a class of smart nano-systems with the
ability to maintain their structure after stimulation.
According to this feature, several species of nano-systems
had been introduced by researchers in which extrinsic (UV
and magnetic) or intrinsic (pH, redox and temperature)
stimuli agents were used.39,63–65
The other advantage of this nanocarrier is its high
loading capacity which is near about 160% for doxorubi-
cin and also its sustain release behavior during 14 days. So
far, several types of nano-systems with different strategies
have been chosen for delivering doxorubicin to its targeted
site. For example in 2018, Li et al introduced a pH-
responsive supramolecular nano theranostics based on pil-
lararene that showed about 3.67% loading efficiency and
pH-dependent release pattern with about 20% drug release
in pH 6.5 and 70% in pH 4.66 Wallat et al applied a
fluorous polymeric micelle as a vehicle for DOX, in
which drugs were covalently conjugated to the micelles
via a pH-responsive hydrazone linkage and showed about
Figure 14 Effect of different concentrations of nanocapsules on (A) PT and (B) APTT.
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20% drug release during 50 h at pH 5.67 By comparing the
drug loading and releasing behavior of nanocapsule stu-
died in this research with other similar studies,68–70 it
could be concluded that this nanocarrier has much higher
loading efficiency and also could show better performance
in response to the acidic environment of cancer tissue for
releasing drugs.
As an intravenous injectable drug carrier, the effect of
nanocapsules on RBC, and blood immune system were
also evaluated using different tests that revealed the hemo-
compatibility of the nanocapsules even in the presence of
drug molecules. The cytotoxicity of the nanocapsules
(with/without drug components) was also assessed in nor-
mal and cancer cells. The results of cytotoxicity tests
indicated that drug-loaded nanocapsules do not affect nor-
mal cells while they show distinctive cytotoxicity on
MCF7 cancer cells after 48 h that can be considered as
an evidence for confirming the pH-responsive behavior of
the nanocapsules. Overall, according to these in vitro tests,
this nanocapsule could be introduced as a smart pH-
responsive drug nanocarrier with switchable controlled
release property which can be used for cancer treatment.
Finally, the attendance of Fe2O3 nanoparticles in the
core of nanocapsule turns to recommend it as a diagnostic
agent for magnetic resonance imaging of the targeted
region that can enhance the quality of the imaging by
affecting the T1 and T2 relaxation times.
71
Conclusion
Application of smart nano-systems in pharmacy with the
aim of cancer treatment is the subject of many scientific
studies in the last decade. In this research, a new type of
pH-responsive nanocapsule was fabricated with the ability
of on/off switching drug release to be used as a nano
theranostic agent for cancer simultaneous diagnosis and
therapy. The nanocapsule was consisted of three polymeric
layers including polymeric beta-cyclodextrin, sulfadiazine
functionalized polyacrylic acid and beta-cyclodextrin
attached to the polyethylenimine, in which the inclusion
complex formed between cyclodextrin components and
sulfadiazine donate a pH-responsive property to the
nano-system. The physicochemical and in vitro biological
properties of the nanocapsule were confirmed by different
tests. Results revealed that this is a biocompatible nano-
capsule with about 43 nm size and −42 mV surface charge,
which show 50–160% drug loading capacity and also a
controllable sustained drug release behavior. Representing
the cytotoxicity effect against cancer cells at very low
concentrations along with the pH-responsive drug release
pattern and also an improvement in the therapeutic effi-
ciency of the drug, this nanocapsule is proposed as an
possible therapeutic agent that can eliminate the side
effects on normal cells, as well as, a significant reduction
in the dose of drug usage leading to prevention of drug
resistance behavior of cancer cells. Combination of the
therapeutic features of the nanocapsule with the diagnostic
property of the magnetic nanoparticles which are pre-
sented in the core of this nano-system, introduce this
new type of nanocarrier as a theranostic candidate for
simultaneous diagnosis and therapy of cancer.
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